SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 2, 1999 HEMAGEN DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 1-11700 04-2869857 - -------------------------------------------------------------------------------- (State or Other Jurisdiction of (Commission File Number) (I.R.S. Employer Incorporation) Identification No.) 40 Bear Hill Road, Waltham, Massachusetts 02451 ----------------------------------------------- Address of principal executive offices, including zip code Registrant's telephone number, including area code: (781) 890-3766 ---------------- ITEM 5. OTHER EVENTS. On July 2, 1999, the Board of Directors of Hemagen Diagnostics, Inc., a Delaware corporation (the "Corporation"), adopted the following two amendments to the Corporation's bylaws: 1. Article VII thereof was amended to provide for the mandatory advancement of expenses incurred by Indemnitees (as defined in Article VII of the Bylaws) as permitted by Section 145(e) of the Delaware General Corporation Law. 2. Article XI thereof was amended to provide that the bylaws may be amended, altered or repealed only by the affirmative vote of the holders of at least two-thirds of the outstanding shares of the common stock of the Corporation. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (a) Not applicable. (b) Not applicable. (c) Exhibits. Exhibit Number Description -------------- ----------- 3.1 Amendment to the Bylaws of Hemagen Diagnostics, Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 2, 1999 HEMAGEN DIAGNOSTICS, INC. By: /s/ Carl Franzblau Name: Carl Franzblau Title: Chief Executive Officer